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ABSTRACT
We have recently shown that rs2304277 variant in the OGG1 glycosidase gene of 
the Base Excision Repair pathway can increase ovarian cancer risk in BRCA1 mutation 
carriers. In the present study, we aimed to explore the role of this genetic variant 
on different genome instability hallmarks to explain its association with cancer risk.
We have evaluated the effect of this polymorphism on OGG1 transcriptional 
regulation and its contribution to telomere shortening and DNA damage accumulation. 
For that, we have used a series of 89 BRCA1 and BRCA2 mutation carriers, 74 BRCAX 
cases, 60 non-carrier controls and 23 lymphoblastoid cell lines (LCL) derived from 
BRCA1 mutation carriers and non-carriers.
We have identified that this SNP is associated to a significant OGG1 transcriptional 
down regulation independently of the BRCA mutational status and that the variant 
may exert a synergistic effect together with BRCA1 or BRCA2 mutations on DNA 
damage and telomere shortening.
These results suggest that this variant, could be associated to a higher cancer 
risk in BRCA1 mutation carriers, due to an OGG1 transcriptional down regulation and 
its effect on genome instability.
INTRODUCTION
Carrying an inherited mutation in the BRCA1 
or BRCA2 genes increases a woman's lifetime risk of 
developing breast and ovarian cancers although there are 
considerable differences in disease manifestation. At the 
age of 70, cumulative cancer risk for BRCA1 and BRCA2 
mutation carriers ranges from 43% to 88% for breast 
cancer development, and from 11% to 59% for ovarian 
cancer [1, 2].
In the context of BRCA1 and BRCA2 mutation 
carriers, it has been shown that other factors such as 
single nucleotide polymorphisms (SNPs) in genes from 
other DNA repair pathways could cause a higher genomic 
instability, hence increasing the cancer risk predisposition 
[3–6]. In this regard, a well-known synthetic lethal 
interaction is described between the BRCA1 and BRCA2 
genes and the poly ADP ribose polymerase (PARP1), 
involved in the Base Excision Repair (BER) pathway [7]. 
BER corrects oxidative lesions in the DNA bases, which 
represent the major portion of endogenous DNA damage 
due to chemical reactions during cellular metabolism 
[8]. These lesions cause different types of DNA damage 
including DNA single-strand breaks (SSBs) or DNA 
double-strand breaks (DSBs) which are the principal 
source of genomic instability [9, 10]. In the presence 
of a defective BRCA1 or BRCA2 background, this 
accumulation of double-strand DNA breaks can persist 
and lead to cell cycle arrest or cell death; making BRCA-
deficient cells extremely sensitive to PARP inhibitors 
(PARPi).
In addition, telomere instability/shortening 
occurring during oxidative and inflammatory stress can be 
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explained by the strong tropism for guanine (G) oxidation 
at the telomere sequence (TTAGGG) [11]. For this reason, 
BER pathway is essential to maintain telomere integrity 
in mammals [12]. In fact, cellular changes due to BER 
defects have been implicated in a multitude of diseases, 
ranging from cardiovascular diseases, arthritis, cancer, as 
well as aging and age-related disorders [13, 14].
SNPs in genes involved in the BER pathway have 
been reported to modify ovarian and breast cancer risk in 
BRCA1 and BRCA2 mutation carriers. In particular, one 
of the most recent examples was described by our group 
for a SNP (rs2304277) in the OGG1 (8-guanine DNA 
glycosylase) gene that was associated with increased 
ovarian cancer risk in BRCA1 mutation carriers [5].  The 
OGG1 gene encodes for a key enzyme involved in the 
first steps of BER that removes a highly mutagenic base, 
8-oxodeoxyguanosine, generated by oxidative stress [15].
In this study, by using two independent sample sets 
with different BRCA status, we have explored the role of 
this polymorphism on OGG1 transcriptional regulation 
and its possible implication on genome instability. With 
this, we would like to explain the cancer risk modifier 
effect that this gene exerts in carriers of BRCA1 and 
BRCA2 mutations.
RESULTS
SNP frequency in FBOC and LCL
We genotyped the SNP rs2304277 in both, FBOC 
and LCLs sample sets, to perform genotype/phenotype 
studies (role of the SNP on: OGG1 mRNA expression, 
telomere studies, and DNA damage). In the FBOC 
samples, we identified 36% of the samples (81/223) 
carrying the variant. The same frequency was reported in 
our previous study analyzing more than 23000 cases and 
controls [5].
The different group of cases and controls presented 
similar frequencies that are summarized in Supplementary 
Table S1. No significant differences were found among 
groups.
From a total of 23 cell lines, 9 harbored the SNP 
(39%). From 16 of the LCL with BRCA1 mutation 
7 LCL harbored the SNP (43%) and from the 7 non-
carrier controls, 2 had the variant (33%) (Supplementary 
Table S2).
Expression of OGG1 in FBOC, Gtex server and 
LCLs
In order to know if the SNP could affect gene 
expression, we first analyzed in the FBOC series the 
OGG1 mRNA expression levels considering both, the 
BRCA mutational status and the presence or absence of 
the OGG1 variant to stratify and compare expression 
values among groups (Figure 1a).
First, we did an independent lineal regression 
analysis in BRCA1/2 mutation carriers to test whether 
cancer status (individuals with or without cancer 
antecedents) could affect OGG1 mRNA levels; because it 
did not affect, we decided to include healthy and affected 
BRCA1/2 mutation carriers in the same group (BRCA1/2) 
for expression  studies, Supplementary Table S3.
In the comparative analysis, we detected an OGG1 
mRNA down regulation in individuals harboring the 
variant. This down regulation was statistically significant 
when we stratified all the FBOC individuals by the presence 
of the variant (with/without) regardless the BRCA status 
(BRCA1/2, BRCAX and non-carrier controls), p=0.011. 
Although. we were not able to detect significant differences 
within each mutational group (non carrier controls, 
BRCA1/2 and BRCAX) probably due to the reduced 
sample size (Figure 1a); a complementary lineal regression 
analysis confirmed a significant down regulation associated 
to the SNP in the non carrier controls (β=-0.63);p=0.049), 
in BRCA1/2 (β=-0.57;p=0.027) and a trend in the BRCAX 
group(β=-0.34;p=0.123), suggesting that the variant 
could be associated per se to lower OGG1 mRNA levels 
independently of the BRCA mutational group.
In parallel, we tested in silico the SNP effect on 
transcriptional regulation in different tissues using the 
Gtex eQTL web server (http://www.gtexportal.org). 
Interestingly, we observed down regulation for whole 
blood, uterus, vagina and ovary, but only the last one 
presented a significant OGG1 transcriptional down 
regulation (p=0.023), Supplementary Table S4. Ovary is 
the tissue where this variant was originally found to be 
associated to an increased cancer risk [5].
Finally, we measured OGG1 mRNA basal levels 
among the 23 LCL considering the BRCA status, and 
presence or absence of the SNP. Only when we group all 
LCL together considering the presence of the SNP we are 
able to detect significant down regulation (p=0.04) Figure 
1b, probably because the sample size was too small to 
detect significant association p-values of OGG1 mRNA 
down regulation within groups (BRCA1 non carriers LCLs 
and BRCA1 LCLs).
Telomere length studies in FBOC
We explored the role of this variant on TL 
maintenance. Hence we measured TL and percentage of 
short telomeres by HT QFISH in the blood cells from 
FBOC patients and non-carrier controls to establish 
genotype/phenotype associations.
We first evaluated the TL distribution in 60 healthy 
women as a function of age to obtain a regression line to 
adjust the TL from FBOC samples. As expected, we found 
a decrease in TL with age, Supplementary Figure S1.
Because mean TL is strongly heritable [16] and 
our series contains related individuals, we used a single 
member (genotype) from each family for both, BRCA 
status and presence or absence of the SNP for the analysis. 
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Whenever possible, we used the index-case of the family 
and if this sample was not available, we used the latest 
genotype included in the family as common criteria of the 
study.
Chemotherapy status, another possible confounding 
factor that alters TL was corrected to perform this analysis 
[17]. We eliminated those cancer patients who were 
undertaking chemotherapy or those within a window of 
2 years since the last cycle of chemotherapy. In total, 13 
BRCA1/2 cases and 26 BRCAX cases were excluded.
Hence, we used a total of 44 controls (19 harboring 
the SNP), 21 BRCA1 carriers (10 harboring the SNP), 28 
BRCA2 carriers (9 harboring the SNP), 1 patient harboring 
mutation in both genes and 38 BRCAX (15 harboring the 
SNP).
First, we did an independent lineal regression 
analysis in BRCA1/2 mutation carriers to test whether 
cancer status (individuals with or without cancer 
antecedents) could affect TL and percentage of short 
telomeres; because it did not affect these 2 factors 
(Supplementary Table S3), we decided to include healthy 
and affected BRCA1/2 mutation carriers in the same group 
(BRCA1/2) for telomere  studies.
In the comparative analysis, Mann Whitney U test 
revealed no significant differences neither in adjusted TL 
nor in percentage of short telomeres between controls 
harboring and not harboring the variant (Figure 2a & 
Figure 2b). However, we observed significant shorter TL 
among BRCA1/2 carriers harboring the variant compared 
to those BRCA1/2 carriers not harboring the SNP 
(p=0.003) or controls (p=0.009), Figure 2a. Additionally, 
increased percentage of short telomeres were detected in 
BRCA1/2 mutation carriers harboring the SNP compared 
to the control group (p=0.018), Figure 2b. In the group of 
BRCAX cases we did not detect any effect of the SNP on 
TL although we found a significant increased percentage 
of short telomeres (p=0,009) compared to controls, Figure 
2a and Figure 2b.
Then, we analyzed all FBOC patients together 
considering the presence/absence of the variant to test the 
effect of the SNP alone, regardless the BRCA mutational 
status. We were not able to observe significant differences 
on TL but we detected a significant increased percentage 
of short telomeres in the group harboring the SNP 
(p=0.016), Figure 2a and Figure 2b.
Linear regression analysis revealed that TL was 
significantly modified by the presence of the SNP in 
the group of patients harboring mutations in BRCA1 or 
BRCA2 genes (BRCA1/2) (β= -1.438; C.I (-2.554 – 
(-0.323); p=0.013), Supplementary Table S3; but not in the 
non-carrier controls or BRCAX groups (data not shown).
Hence, we stratified BRCA1/2 patients according 
to the SNP and we compared the linear model between 
each of the groups (BRCA1/2 with/without the SNP 
and controls). Significant differences were detected in 
BRCA1/2 carriers harboring the SNP when compared 
to those not harboring the SNP (p=0.010) or controls 
(p=0.034), Figure 2c. In fact, we observed a faster 
Figure 1: a. Comparative analysis relative to the OGG1 mRNA expression levels between FBOC groups (BRCA1 & BRCA2, 
BRCAX) and controls according the presence of the OGG1 SNP. Control group harbouring the variant showed a statistical trend of 
lower OGG1 mRNA levels (p=0.07); while we didn’t detect significant differences in OGG1 transcriptional levels within BRCA1 and 
BRCA2 group due to the presence of the SNP (p=0.11). When all FBOC samples, were stratified according to the presence of the SNP, we 
observed significant lower OGG1 mRNA expression levels in the individuals harbouring the variant (p=0.011). Line at mean with standard 
error mean (SEM) b. Transcriptional mRNA basal levels of OGG1 in Lymphoblastoid cell lines (LCLs). Each dot at the graph, represent 
the mean OGG1 mRNA values from two independent measurements (two clones of each sample) for most LCL analyzed (20/23), for 3 
samples we could measure only once. We found that LCL harbouring the SNP presented significant lower OGG1 mRNA levels when 
compared to those who did not harbour the SNP (p=0.04). Line at mean with standard error mean (SEM).
a b
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telomere shortening (slope) in the group of patients 
harboring both, the BRCA1/2 mutation together with the 
SNP, compared to those who did not harbor the SNP, or 
the control group, Figure 2c (legend).
Telomere length study in LCLs
We compared telomere shortening during normal 
replication among the BRCA1 LCLs  to confirm 
experimentally the faster telomere shortening (slopes) 
observed in the FBOC patients who harbored the 
BRCA1/2 mutation together with the variant. Additionally, 
we measured and compared the accumulation of short 
telomeres along the cell culture.
Due to technical issues and the differences in 
growth rate, we could only use a set of 8 out of the 16 
LCLs harboring mutation in BRCA1 gene to follow the 
Figure 2: a. Distribution of the TL (Kb) values adjusted for age according to mutational status. We did not detect significant 
differences in TL for the control group due to the presence of the SNP; while TL was significantly shorter in BRCA1/2 mutation carriers 
harbouring the variant when compared to non carriers of the SNP (p=0.003) or controls(0.009). We were not able to find any difference in 
TL among the BRCAX group of patients. Additionally we stratify all the FBOC samples according to the presence of the variant and we did 
not detect any significant difference in TL between carriers and non carriers. Line at mean with standard error mean (SEM) b. Comparative 
analysis among FBOC genotypes regarding the percentage of short telomeres (<3Kb). We did not detect significant differences in 
the percentage of short telomeres neither in the control nor in the BRCA1/2 groups when the variant was present; however BRCA1/2 or 
BRCAX harbouring the variant presented significant higher % of short telomeres compared to controls(all)(p=0.018; p=0.009). Additionally 
we stratify all the FBOC samples according to the presence of the variant, and we could detect a significant higher % of short telomeres in 
those samples harbouring the SNP (p=0.016) Line at mean with standard error mean (SEM) c. Telomere shortening lines in BRCA1 or 
BRCA2 mutations carriers group (BRCA1/2) with and without the variant, and the non-carriers controls. TL (Kb) is represented in 
this graph according to age (years). Regression line is draw in green colour for controls (y=-0.080*age+13.367), blue colour for BRCA1/2 
patients (y=-0.537*age+12.188) and red colour for BRCA1/2 with the variant (y=-0.0918*age+12.705). F-test: BRCA1/2 vs BRCA1/2 
rs2304277 (p=0.010); Controls vs BRCA1/2 rs2304277 (p=0.034).
a b
c
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telomere shortening during 55 passages. From the 8 LCL 
with mutation in BRCA1 gene 3 presented also the SNP.
Our results revealed significant faster telomere 
shortening after 55 cell culture passages, in the group of 
samples harboring BRCA1  mutation together with the 
SNP (p=0.033). This result is similar from the previous 
obtained in patients suggesting that this event is taking 
place only when BRCA1 mutation and the variant are 
together, Figure 3a. We could also confirm a significant 
accumulation of short telomeres in the LCL harboring 
the BRCA1 mutation together with the variant after 55 
passages of cell culture (p=0.03), Figure 3b.
DNA damage
To test the possible contribution of the SNP to a 
higher DNA damage we measured the mean γH2AX 
intensity signal in the cell nucleus at basal conditions (first 
passage and no irradiation).
We plotted all the γH2AX values from the LCL in 
a cumulative frequency histogram to establish a damage 
threshold above which we observed an exponentially 
increase in the γH2AX intensity values, which indicates 
the cells with a clear nuclear DNA damage. We established 
the threshold in 95 arbitrary units of γH2AX of nuclear 
intensity (Figure 4a).
Then, we calculated the frequency of damaged cells 
among LCLs with different genotypes and the intensity 
of the nuclear γH2AX signal in these cells to evaluate the 
possible impact of the OGG1 SNP on DNA damage. We 
found minimum differences in the percentage of damaged 
cells associated to the presence of the SNP (5.8% and 
6.3% in LCLs with and without the SNP, respectively). 
However, the intensity of the damage was significantly 
higher in LCLs harboring the SNP (p=0.010) compared to 
those not harboring the variant, Figure 4b.
DISCUSSION
We have previously found that the OGG1 SNP 
rs2304277may be a modifier of cancer risk in BRCA1 
mutation carriers [5]. OGG1 belongs to the BER pathway 
that plays an important role correcting DNA lesions 
originated by oxidative stress. These lesions are the 
principal source of genomic instability and can drive to 
cancer development. In this study we have shown how this 
variant can contribute to increase cancer risk in BRCA1 
carriers, by reducing the mRNA OGG1 expression levels, 
increasing the DNA damage as a consequence of genomic 
instability generated, and shortening the telomeres in a 
synergic way with the BRCA1 mutation.
Because rs2304277 is located 1.8Kb downstream 
of 3’UTR region of the OGG1 and post transcriptional 
modifications, like potential illegitimate microRNA target 
site [18, 19], could be altering normal OGG1 mRNA 
regulation, we decided to explore the role of this SNP on 
transcriptional regulation using two set of samples. The first 
set consisted in 223 blood samples from controls and FBOC 
patients with a heterogeneous BRCA mutational status 
(BRCA1, BRCA2 and BRCAX) and the second was a panel 
of 23 LCLs derived from BRCA1 mutation carriers and 
non-carrier controls. The percentage of heterozygotes for 
Figure 3: We measured TL differences between passage nº1 and passage nº55 for each LCL, to calculate telomere 
shortening/ lengthening in Kb and the gain or lose of critical short telomeres(<3Kb) a. Telomere length lose or gain after 
55 passages of culture among BRCA1 mutated LCLs. Significant telomere shortening in LCL harbouring BRCA1 mutation together with 
the SNP was detected after 55 passages compared to those not harbouring the variant (p=0.033). Line at mean with standard error means 
(SEM) b. Percentage of critical short telomeres gain or lose after 55 passages of culture among among BRCA1 mutated  LCLs. 
Significant increased amount of short telomeres was found in the LCL harbouring BRCA1 mutation together with the SNP after 55 passages 
compared to those not harbouring the variant (p=0.03). Line at mean with standard error means (SEM).
a b
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the SNP in the FBOC and LCL set of samples was 36% and 
39%, respectively, which was the expected frequency [5].
We confirmed in both sample sets (FBOC series 
and LCL) significant lower expression of OGG1 mRNA 
transcript associated to the SNP, independently of BRCA 
mutational status, (Figure 1a & Figure 1b). We extended 
the analysis using Gtex eQTL dB (http://www.gtexportal.
org) looking for the SNP effect over OGG1 mRNA 
levels in different tissues and we found significant down 
regulation in ovary (p=0.023) tissue where this SNP was 
initially found to be associated to a higher cancer risk, 
Supplementary Table S4.
These results suggest that this cancer risk variant is 
likely associated with mRNA OGG1 transcriptional down 
regulation which can potentially lead to higher genome 
instability due to a defective 8-oxoG repair capacity. 
In this way, the aberrant accumulation of 8-oxoG was 
previously associated with faster development of lung 
adenocarcinoma in OGG1 knock-out mice models [20] 
while in transgenic mice it was demonstrated that over 
expression of OGG1 attenuated breast cancer progression 
and metastasis through a reduction in the oxidative damage 
[21]. All these data suggest a critical role of this gene in 
cancer development and progression which, together with 
BRCA mutations could result in higher genome instability 
and increased cancer risk.
Given the role of the BER pathway and in particular 
the OGG1 enzyme on telomere repair [11, 22], we 
explored the impact of this SNP on some features related 
to telomere biology considered as hallmarks of genome 
instability, such as telomere shortening or the percentage 
of critically short telomeres. We found in the linear 
regression analysis, that the SNP may be a TL modifier 
for BRCA1 and BRCA2 mutations carriers (p=0.013). 
Carriers of BRCA1/2 mutations and OGG1 SNP presented 
a significant shorter TL compared to controls (p=0.009) 
and mutation carriers not harboring the SNP (p=0.003) 
(Figure 2a), likely due to an accelerated telomere 
shortening during life-time (Figure 2c). We also found an 
increase of short telomeres in those individuals harboring 
the SNP, regardless the BRCA mutational status (p=0.016) 
(Figure 2b).
These results were experimentally validated in our 
LCL set by measuring TL after 55 passages. We could 
confirm a significant faster telomere shortening in the 
group of samples harboring a BRCA1 mutation together 
the SNP (p=0.033) (Figure  3a), which correlated with a 
significant accumulation of short telomeres after a total 
of 55 cell culture passages (p=0.03) (Figure 3b). Our 
results point to a synergistic effect of the SNP and the 
BRCA1 mutation on telomere shortening. This telomere 
instability may be due to the cell tropism for the 
accumulation of oxidative lesions at the telomeric region 
[23, 24] in the context of defective BER performance 
[22] triggered by the SNP effect on OGG1 down 
regulation. In this sense other authors have reported that 
SNPs located in the 3’UTR region of OGG1 could be 
associated with a lower 8-oxoG repair activity being 
particularly sensitive to the cellular redox status. [25, 26]
The region represented by the SNP has been 
previously spotted by other authors who also found 
associations with different cancer types [27–29]. Then, 
Figure 4: a. Threshold of γH2AX nuclear intensity damage. We selected the intensity value of 95(arbitrary units) as a cut of to establish 
the damaging signal intensity because this was the value in where the distribution change shape exponentially, indicating which are the 
normal and the abnormal (damaging)values. b. Comparative analysis regarding the signal intensity of γH2AX at the nucleus among 
the LCL genotypes. The effect of the variant is not significant in the control group (p>0.05) while in the group of cells carrying mutation 
in BRCA1, we found higher γH2AX signal intensity when the variant was present (p = 0.09). We stratified all the 23 LCL according the 
presence of the variant and we detected significant higher γH2AX intensity in the carriers of the variant (p =0.010). Line at mean with 
standard error means (SEM).
a b
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we tested whether this SNP could have an impact on DNA 
damage, measured in this case by γH2AX, a DNA damage 
marker of DSB [30].
Using the LCL panel, we compared the percentage 
of damaged cells and its nuclear γH2AX signal intensity 
among different genotypes at basal conditions (first 
passage and no irradiation). Despite we found a similar 
percentage of damaged cells among LCLs with and 
without the variant (5.8% and 6.3%, respectively), 
we could detect that those LCLs harboring the SNP, 
presented significantly higher γH2AX signal intensity at 
the nucleus, pointing to a more profound DNA damage 
(p=0.010) (Figure 4b). These results are similar to other 
reported in the literature establishing association between 
SNPs in OGG1 at the same gene region with an increased 
DNA damage/genome instability due to an impaired BER 
performance [6, 25-27, 31, 32]
In summary, we have identified that the OGG1 SNP 
itself contributes to a higher nuclear DNA damage intensity, 
probably due to a defective BER performance triggered 
by OGG1 transcriptional down regulation. Additionally, 
our results suggest a synergistic effect between BRCA1 
or BRCA2 mutations with the SNP rs2304277 on specific 
telomere instability hallmarks, such as telomere shortening 
and the accumulation of short telomeres, when both genetic 
events are present in the cell. These molecular processes 
could explain the relation between this SNP and BRCA1 or 
BRCA2 mutations, on cancer risk.
MATERIALS AND METHODS
Familial breast and ovarian cancer (FBOC)
We studied two different set of samples: A first 
group, was composed by 223 individuals belonging to 
121 families meeting high risk criteria and screened for 
deleterious mutations in BRCA1 and BRCA2 genes, as 
previously reported [1]. 24 carried a deleterious mutation 
in BRCA1, 25 in BRCA2, 1 family harbored both BRCA1 
and BRCA2 mutations and 71 did not carry any mutation 
(BRCAX).
Sixty individuals were used as non-carrier controls: 
They were relatives of BRCA1/2 carriers, who didn’t 
have any personal cancer antecedent and didn’t harbor 
the corresponding familial mutation in BRCA1 or BRCA2 
genes. General characteristic of this series are described 
in Table 1.
All cases and controls signed an appropriate 
informed consent and the proposal was approved by the 
ethics committee at the Fuenlabrada University Hospital.
We used this set of samples (BRCA1/2 carriers, 
BRCAX cases and controls) to calculate the percentage of 
heterozygotes harboring the SNP, to quantify the OGG1 
mRNA levels in peripheral blood, and to perform telomere 
studies using fresh blood cells, Table 1.
Lymphoblastoid cell lines
A second set of 23 LCLs was established by Epstein 
Barr virus transformation of peripheral blood lymphocytes 
from sixteen healthy women carrying heterozygous 
mutations in BRCA1 and seven non-carrier relatives used as 
controls. Mutational analysis had been previously performed 
by Sanger sequencing, Supplementary Table S2. None of 
the women included in the study had personal antecedents 
of cancer. This LCL panel has been previously described 
by our group [33]. Cell lines were cultured in RPMI-1640 
media (Sigma-Aldrich) supplemented with non-heat-
inactivated 20% fetal bovine serum (Sigma-Aldrich), 
penicillin-streptomycin (Gibco) and Fungizone (Gibco). 
The cultures were carried out in 25 cm2 flasks (Corning) at 
37°C in 5% CO2 atmosphere and cell lines were maintained 
in exponential growth by daily dilution to 106 cells/ml of 
full media.
Table 1: Description of the analyzed series and the different studies performed
Families (n) Healthy carriers
Affected 
carriers
c Non-carriers 
controls Total
Median 
age, 
(range)
SNP 
Genotyping
Expression 
studies
dTL 
studies
BRCA1, (24) 18 20 13 51 45, (23-78y) 51 48 30
BRCA2, (25) 27 21 25 73 50, (22-87y) 73 64 46
aBRCA1 + BRCA2, (1) 1 2 1 4 54, (42-61y) 4 4 3
b BRCAX, (71) - 74 21 95 49, (20-85y) 95 92 53
Total FBOC, (121) 46 117 60 223 49, (18-87y) 223 209 132
a Refers to a family harboring mutations in both BRCA1 and BRCA2 genes.
b Non BRCA1 or BRCA2 families.
c Non carrier controls were composed by family relatives without any antecedents of cancer and negative for BRCA1 or 
BRCA2 mutations.
d Sample size used in TL studies after heritability correction and exclusion of patients who were undertaking chemotherapy 
(see manuscript in results section, TL studies in FBOC).
Oncotarget25822www.impactjournals.com/oncotarget
We used this set of samples to measure OGG1 
mRNA expression levels, DNA damage at basal conditions 
and whenever possible telomere shortening and the 
percentage of short telomeres gained/lost after 55 passages 
of cell culture.
SNP genotyping
The SNP rs2304277, showed the strongest 
association to cancer risk among all the SNP covering 
the gene (tagged or imputed) that were included in our 
previous study [5]. This SNP is located 1.8 kb downstream 
the 3′UTR (untranslated region) of the gene. Despite we 
did not find better results for a more plausible causal SNP, 
we could detect that SNPs in high linkage disequilibrium 
(LD) with rs2304277, presented similar cancer association 
direction and p-values [5]. Hence, we considered 
rs2304277 as a good representative of that gene region, 
which is detailed in Supplementary Table S5.
DNA was extracted from patient’s peripheral blood 
(FBOC) and from cultured LCLs using MagNAPure LC 
2.0 (Roche Diagnostics, Indianapolis, Indiana) following 
manufacturer’s conditions. DNA quantification and quality 
was assessed by NanoDrop® (ND-1000 V3.7.1).
Flanking region of the rs2304277 was amplified 
using PCR method with the following primers: OGG1 
“rs2304277-G>A”-F: 5’ GACCTTTCTCGGACCCCATA 
3’OGG1 “rs2304277-G>A”-R: 5’ ACTCCTCCCCAT 
CCCTACC 3’ and the product was genotyped using 
Sanger method using ABI3700.
RNA expression analysis
Using TRIzol Reagent (Ambion®, Life Techonogies) 
according to manufacturer’s instructions, RNA was 
extracted from peripheral blood cells. Both RNA quantity 
and quality were assessed by NanoDrop® (ND-1000 
V3.7.1).
1 µl of cDNA at a final concentration 10-20 ng/µl 
was loaded in triplicate, with GoTaq® qPCR MasterMix 
1x (Promega); OGG1 cDNA primers (F/R) and GAPDH 
cDNA primers (F/R) in final concentration of 500nM. All 
the mentioned reagents were used following manufacture’s 
conditions. Delta Delta Ct method was run in ABI quant 
studio S7.
cDNA-OGG1-F:5’ CTCCACTCCTGCCCTGTG 3’
cDNA-OGG1-F:5’ 
AGAGAAAAGGCATTCGATGG 3’
cDNA-GAPDH-F: 5’ CTCCACTCCTGCCCTGTG 3’
cDNA-GAPDH-F: 5’ AGAGAAAAGGCATTCGA 
TGG3’
Telomere length measurement (TL)
High throughput quantitative fluorescence in situ 
hybridization (HT-QFISH) with automated fluorescence 
microscopy was performed as previously described [34]. 
Briefly, Peripheral Blood Mononuclear cells (PBMCs) 
were separated by Histopaque-1070 (Sigma-Aldrich) 
gradient centrifugation. Cells were then counted and 
plated (80 000 – 100 000 cells/well in clear bottomed 
black-well 96-well plates precoated with 0.001% (poly)
L-lysine solution (Sigma-Aldrich, St. Louis, MO) for 30 
minutes at 37ºC. 4´,6-diamino-2-phenylindole (DAPI) 
was used for nucleus staining and a fluorescent peptide 
nucleic acid (PNA) Cy3 probe against telomeric repeats 
was used for telomere detection. TL values were analyzed 
using individual telomere spots in a per cell basis 
(Approximately 90000 telomere spots per sample, which 
represents around 3500 cells). Fluorescence intensities 
were then converted into Kb using L5178-R, L5178-S 
and CCRF-CEM cells as calibration standards, which have 
stable telomere lengths of 79.7 Kb, 10.3Kb and 7.5 kb, 
respectively[35]. Samples were analyzed in duplicate, or 
triplicate in the case of calibration standards. A TL <3Kb 
was defined as short. The load of short telomeres was 
estimated as the percentage of short telomeres (number 
of short telomeres divided by total number of measured 
telomeres) in each participant.
DNA damage
LCLs were cultured 4 hours before fixation with 
4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, Philadelphia, USA). Two hours before fixation, 
cells were counted and seeded into a poly-L-lysine-coated 
(Sigma-Aldrich) µCLEAR bottom 96-well plate (Greiner 
Bio-One) at a density of 75,000 cells per 100ul full 
media per well. LCL were then left for 2 hours in order 
to attach to the surface of the wells, fixed for 15 min at 
room temperature, permeabilized in 0.5% Triton X-100 in 
PBS for 20 minutes at 4°C and stained with primary and 
secondary antibodies and 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI) to visualize nuclei. To detect 
γ-H2AX we used mouse monoclonal anti-phospho-
histone H2AX antibody (Millipore; #05-636). Alexa 
Fluor 488 from molecular probes (Invitrogen; #A-11034) 
was used, and fluorescent images were automatically 
taken for each well of the 96-well plate using an Opera 
High-Content Screening System (Perkin Elmer). Pictures 
were taken under non-saturating conditions using a 40x 
magnification lens to calculate the γ-H2AX nuclear signal 
intensity.
Statistical analysis
Pearson's chi-squared test was used to calculate 
whether differences in the frequency of the SNP among the 
FBOC groups were significant, Supplementary Table S1.
Telomere length (Kb) was adjusted to the age, using 
the best fit line controls (y= -0.067* age (years) +12.785). 
The difference between the actual and the predicted value 
was calculated for each sample.
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For the comparative analysis we have considered 
healthy or affected (patients with cancer antecedents) 
BRCA1 and BRCA2 mutation carriers in a single 
group BRCA1/2. We performed an independent linear 
regression analysis, using cancer status as a binary 
variable to test whether it could affect significantly OGG1 
mRNA expression, TL or percentage of short telomeres 
(Supplementary Table S3).
Kolmogorov-Smirnov test was used to evaluate 
if the data sets were normally distributed. For the 
comparative analysis (OGG1 mRNA expression, Telomere 
studies and γH2AX nuclear intensity signal), statistically 
significant differences were assessed by Mann-Whitney 
U test for not normal distributions (Figures: 1a, 1b, 2a, 
2b, 3a, 3b, 4b) and complementary, using lineal regression 
analysis whenever necessary:
· Regarding the expression studies, lineal regression 
model including as explanatory variable OGG1 SNP, was 
run to test whether this variable could affect OGG1 mRNA 
levels in each FBOC group (BRCA1/2 carriers, BRCAX 
cases and non-carriers  controls).
· In relation with the TL studies, a linear regression 
model was created including as explanatory variables 
age and the SNP among the different genotypes. Then, 
if significant differences were found, a separate model 
was created for each of the genotypes: i) Controls (all) 
ii) BRCA1/2 carriers harboring the variant iii) BRCA1/2 
carriers without the variant. Significant differences among 
the models were tested with F-test (Figure 2c).
For all the analysis, bilateral p values less than 
p<0.05 where considered significant.
Statistical calculations were done by SPSS version 
18 (SPSSI« Inc, Chicago, Illinois), the R project for 
statistical computing, GraphPad Prim 5.03 (San Diego, 
California), and graphics were performed by GraphPad 
Prim 5.03 (San Diego, California)
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